QGEN · Qiagen N.V.
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
QGEN
this stock
Qiagen N.V.
|
$8.65B | -5.9% | +5.7% | — | 3.8% |
|
TMO
Thermo Fisher Scientific Inc.
|
$213.65B | -0.1% | +0.4% | 31.1 | 1.4% |
|
DHR
Danaher Corp /De/
|
$140.36B | -12.4% | +8.5% | 35.4 | 1.4% |
|
IDXX
Idexx Laboratories Inc /De
|
$46.07B | -13.6% | +10.4% | 41.1 | 2.7% |
|
A
Agilent Technologies, Inc.
|
$39.85B | +4.3% | +6.4% | 28.3 | 2.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| QGEN | +0.3% | +10.4% | -17.1% | +1.3% | -5.9% |
| SPY | +5.5% | +3.3% | +11.3% | +3.1% | +12.9% |
| vs SPY | -5.2% | +7.1% | -28.4% | -1.7% | -18.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.